Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility located in Dabhasa, Gujarat. The EIR was issued post the last inspection of the facility conducted from April 8, 2024 to April 12, 2024. The inspection concluded with no observations and the facility receiving an inspection classification of ‘No Action Indicated’ (NAI). The facility is a part of Lupin Manufacturing Solutions (LMS), which is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and Contract Development and Manufacturing Operations.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
